Risk assessment: controversies and management of moderate- to high-risk individuals
- PMID: 15725110
- DOI: 10.1111/j.1075-122X.2005.217163.x
Risk assessment: controversies and management of moderate- to high-risk individuals
Abstract
With the current understanding of sporadic and familial breast cancer, it is now possible to identify individuals who have a moderate or high risk of breast cancer. For these individuals, it is useful to perform formal cancer risk assessment and develop an individualized risk reduction plan, including a tailored plan for cancer screening, preventive therapy, and/or prophylactic surgery. Assessment using a predictive model such as the Gail model is particularly useful in individuals at increased risk for sporadic breast cancer. In addition, assessment of risk based on histologic appearance of benign or premalignant breast lesions can be used to identify individuals for whom more aggressive risk reduction strategies are warranted. For individuals who are at risk for familial cancer syndromes, other predictive models are more appropriate. For this extremely high-risk group, genetic testing for mutations in familial cancer susceptibility genes is helpful to identify individuals who would benefit from even more aggressive cancer risk reduction strategies. Strategies to identify the levels of risk for breast cancer, including the identification of moderate, high, or very high risk groups are discussed. Management options for these groups are presented, including who to consider for more aggressive screening, chemoprevention, or prophylactic surgery. Current recommendations for screening, chemoprevention, and surgery for each risk group are presented. The ability to identify individuals at high risk for breast cancer now enables clinicians to intervene to reduce the risk of breast cancer. Aggressive screening, preventive therapy, and prophylactic surgery in moderate- to high-risk individuals should, in the future, significantly reduce the incidence of invasive breast cancer.
Similar articles
-
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.Gynecol Oncol. 2007 Nov;107(2):159-62. doi: 10.1016/j.ygyno.2007.09.031. Gynecol Oncol. 2007. PMID: 17950381
-
Screening and follow-up of the patient at high risk for breast cancer.Obstet Gynecol. 2007 Dec;110(6):1404-16. doi: 10.1097/01.AOG.0000295638.83285.97. Obstet Gynecol. 2007. PMID: 18055740 Review.
-
Hereditary breast cancer. Risk assessment of patients with a family history of breast cancer.Can Fam Physician. 1999 Jan;45:104-12. Can Fam Physician. 1999. PMID: 10889863 Free PMC article. Review.
-
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.Gynecol Oncol. 2005 May;97(2):457-67. doi: 10.1016/j.ygyno.2005.01.039. Gynecol Oncol. 2005. PMID: 15863145
-
Management of the BRCA mutation carrier or high-risk patient.Clin Plast Surg. 2007 Jan;34(1):15-27; abstract v. doi: 10.1016/j.cps.2006.11.010. Clin Plast Surg. 2007. PMID: 17307068 Review.
Cited by
-
Objective and subjective breast cancer risk: relationships with natural killer cell activity and psychological distress in healthy women.Cancer Nurs. 2010 Nov-Dec;33(6):411-20. doi: 10.1097/NCC.0b013e3181dc37a1. Cancer Nurs. 2010. PMID: 20562616 Free PMC article.
-
Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models.Fam Cancer. 2008;7(3):199-212. doi: 10.1007/s10689-007-9176-2. Epub 2007 Dec 21. Fam Cancer. 2008. PMID: 18097771
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical